USFDA Issues Warning Letter to Alembic Pharmaceuticals Over Bioequivalence Study, Citing ICF Observation
Alembic Pharmaceuticals Limited has been informed that the United States Food and Drug Administration (USFDA) issued a Warning Letter concerning a bioequivalence study conducted at its Bioequivalence Facility. The warning relates specifically to observations regarding the Informed Consent Form (ICF).The USFDA issued the Warning Letter on July 10, 2026, following an inspection conducted between March 3, 2025, and March 7, 2025. Alembic Pharmaceuticals has stated that the observations detailed in the letter do not relate to data integrity within the study.
The company noted receiving the Warning Letter on July 12, 2026. Based on its preliminary assessment, Alembic pharmaceuticals reported that the warning does not impose any restriction on the operations of its Bioequivalence Facility. The company is coordinating with the Clinical Investigator and is preparing an appropriate response to the USFDA within the stipulated timeline.
The details concerning the action taken by the authority and the impact on the business have been assessed as follows:
| Authority | United States Food and Drug Administration (USFDA) |
|---|---|
| Nature of Action | Warning Letter issued to the Clinical Investigator associated with a bioequivalence study. |
| Date of Receipt | The Company became aware of the Warning Letter on July 12, 2026. |
| Details of Violation | The warning pertains to observations regarding the Informed Consent Form (ICF) in relation to the bioequivalence study. Observations do not relate to data integrity. |
| Impact Assessment | No material financial impact has been identified at this stage. Alembic is evaluating the matter and coordinating with the Clinical Investigator for the response submission to USFDA. |
APLLTD Stock Price Movement
Alembic Pharmaceuticals Limited shares slipped by 0.88% today to settle at ₹831.05, falling ₹7.40 from its previous close. The stock saw 101,420 shares change hands during the trading session.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.